Efficacy of 12 weeks oral beta‐alanine supplementation in patients with chronic obstructive pulmonary disease: a double‐blind, randomized, placebo‐controlled trial
Background Beta‐alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes exercise capacity in healthy older adults. As patients with chronic obstructive pulmonary disease (COPD) suffer from elevated exerc...
Saved in:
| Published in | Journal of cachexia, sarcopenia and muscle Vol. 13; no. 5; pp. 2361 - 2372 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Heidelberg
John Wiley & Sons, Inc
01.10.2022
Wiley Open Access/Springer Verlag John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2190-5991 2190-6009 2190-6009 |
| DOI | 10.1002/jcsm.13048 |
Cover
| Abstract | Background
Beta‐alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes exercise capacity in healthy older adults. As patients with chronic obstructive pulmonary disease (COPD) suffer from elevated exercise‐induced muscle oxidative/carbonyl stress and acidosis, and from reduced muscle carnosine stores, it was investigated whether BA supplementation augments muscle carnosine and induces beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress in patients with COPD.
Methods
In this double‐blind, randomized, placebo (PL)‐controlled trial (clinicaltrials.gov identifier: NCT02770417), 40 patients (75% male) with COPD (mean ± standard deviation: age 65 ± 6 years; FEV1% predicted 55 ± 14%) were assigned to 12 weeks oral BA or PL supplementation (3.2 g/day). The primary outcome, i.e. muscle carnosine, was quantified from m. vastus lateralis biopsies obtained before and after intervention. Co‐primary outcomes, i.e. incremental and constant work rate cycle capacity, were also assessed. Linear mixed model analyses were performed. Compliance with and side effects of supplement intake and secondary outcomes (quadriceps strength and endurance, and muscle oxidative/carbonyl stress) were also assessed.
Results
Beta‐alanine supplementation increased muscle carnosine in comparison with PL in patients with COPD (mean difference [95% confidence interval]; +2.82 [1.49–4.14] mmol/kg wet weight; P < 0.001). Maximal incremental cycling capacity (VO2peak: +0.5 [−0.7 to 1.7] mL/kg/min; P = 0.384, Wpeak: +5 [−1 to 11] W; P = 0.103) and time to exhaustion on the constant work rate cycle test (+28 [−179 to 236] s; P = 0.782) did not change significantly. Compliance with supplement intake was similar in BA (median (quartile 1–quartile 3); 100 (98–100)%) and PL (98 (96–100)%) (P = 0.294) groups, and patients did not report side effects possibly related to supplement intake. No change was observed in secondary outcomes.
Conclusions
Beta‐alanine supplementation is efficacious in augmenting muscle carnosine (+54% from mean baseline value) without side effects in patients with COPD in comparison with PL. However, accompanied beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress were not observed. |
|---|---|
| AbstractList | Abstract Background Beta‐alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes exercise capacity in healthy older adults. As patients with chronic obstructive pulmonary disease (COPD) suffer from elevated exercise‐induced muscle oxidative/carbonyl stress and acidosis, and from reduced muscle carnosine stores, it was investigated whether BA supplementation augments muscle carnosine and induces beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress in patients with COPD. Methods In this double‐blind, randomized, placebo (PL)‐controlled trial (clinicaltrials.gov identifier: NCT02770417), 40 patients (75% male) with COPD (mean ± standard deviation: age 65 ± 6 years; FEV1% predicted 55 ± 14%) were assigned to 12 weeks oral BA or PL supplementation (3.2 g/day). The primary outcome, i.e. muscle carnosine, was quantified from m. vastus lateralis biopsies obtained before and after intervention. Co‐primary outcomes, i.e. incremental and constant work rate cycle capacity, were also assessed. Linear mixed model analyses were performed. Compliance with and side effects of supplement intake and secondary outcomes (quadriceps strength and endurance, and muscle oxidative/carbonyl stress) were also assessed. Results Beta‐alanine supplementation increased muscle carnosine in comparison with PL in patients with COPD (mean difference [95% confidence interval]; +2.82 [1.49–4.14] mmol/kg wet weight; P < 0.001). Maximal incremental cycling capacity (VO2peak: +0.5 [−0.7 to 1.7] mL/kg/min; P = 0.384, Wpeak: +5 [−1 to 11] W; P = 0.103) and time to exhaustion on the constant work rate cycle test (+28 [−179 to 236] s; P = 0.782) did not change significantly. Compliance with supplement intake was similar in BA (median (quartile 1–quartile 3); 100 (98–100)%) and PL (98 (96–100)%) (P = 0.294) groups, and patients did not report side effects possibly related to supplement intake. No change was observed in secondary outcomes. Conclusions Beta‐alanine supplementation is efficacious in augmenting muscle carnosine (+54% from mean baseline value) without side effects in patients with COPD in comparison with PL. However, accompanied beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress were not observed. Beta-alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes exercise capacity in healthy older adults. As patients with chronic obstructive pulmonary disease (COPD) suffer from elevated exercise-induced muscle oxidative/carbonyl stress and acidosis, and from reduced muscle carnosine stores, it was investigated whether BA supplementation augments muscle carnosine and induces beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress in patients with COPD.BACKGROUNDBeta-alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes exercise capacity in healthy older adults. As patients with chronic obstructive pulmonary disease (COPD) suffer from elevated exercise-induced muscle oxidative/carbonyl stress and acidosis, and from reduced muscle carnosine stores, it was investigated whether BA supplementation augments muscle carnosine and induces beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress in patients with COPD.In this double-blind, randomized, placebo (PL)-controlled trial (clinicaltrials.gov identifier: NCT02770417), 40 patients (75% male) with COPD (mean ± standard deviation: age 65 ± 6 years; FEV1 % predicted 55 ± 14%) were assigned to 12 weeks oral BA or PL supplementation (3.2 g/day). The primary outcome, i.e. muscle carnosine, was quantified from m. vastus lateralis biopsies obtained before and after intervention. Co-primary outcomes, i.e. incremental and constant work rate cycle capacity, were also assessed. Linear mixed model analyses were performed. Compliance with and side effects of supplement intake and secondary outcomes (quadriceps strength and endurance, and muscle oxidative/carbonyl stress) were also assessed.METHODSIn this double-blind, randomized, placebo (PL)-controlled trial (clinicaltrials.gov identifier: NCT02770417), 40 patients (75% male) with COPD (mean ± standard deviation: age 65 ± 6 years; FEV1 % predicted 55 ± 14%) were assigned to 12 weeks oral BA or PL supplementation (3.2 g/day). The primary outcome, i.e. muscle carnosine, was quantified from m. vastus lateralis biopsies obtained before and after intervention. Co-primary outcomes, i.e. incremental and constant work rate cycle capacity, were also assessed. Linear mixed model analyses were performed. Compliance with and side effects of supplement intake and secondary outcomes (quadriceps strength and endurance, and muscle oxidative/carbonyl stress) were also assessed.Beta-alanine supplementation increased muscle carnosine in comparison with PL in patients with COPD (mean difference [95% confidence interval]; +2.82 [1.49-4.14] mmol/kg wet weight; P < 0.001). Maximal incremental cycling capacity (VO2 peak: +0.5 [-0.7 to 1.7] mL/kg/min; P = 0.384, Wpeak: +5 [-1 to 11] W; P = 0.103) and time to exhaustion on the constant work rate cycle test (+28 [-179 to 236] s; P = 0.782) did not change significantly. Compliance with supplement intake was similar in BA (median (quartile 1-quartile 3); 100 (98-100)%) and PL (98 (96-100)%) (P = 0.294) groups, and patients did not report side effects possibly related to supplement intake. No change was observed in secondary outcomes.RESULTSBeta-alanine supplementation increased muscle carnosine in comparison with PL in patients with COPD (mean difference [95% confidence interval]; +2.82 [1.49-4.14] mmol/kg wet weight; P < 0.001). Maximal incremental cycling capacity (VO2 peak: +0.5 [-0.7 to 1.7] mL/kg/min; P = 0.384, Wpeak: +5 [-1 to 11] W; P = 0.103) and time to exhaustion on the constant work rate cycle test (+28 [-179 to 236] s; P = 0.782) did not change significantly. Compliance with supplement intake was similar in BA (median (quartile 1-quartile 3); 100 (98-100)%) and PL (98 (96-100)%) (P = 0.294) groups, and patients did not report side effects possibly related to supplement intake. No change was observed in secondary outcomes.Beta-alanine supplementation is efficacious in augmenting muscle carnosine (+54% from mean baseline value) without side effects in patients with COPD in comparison with PL. However, accompanied beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress were not observed.CONCLUSIONSBeta-alanine supplementation is efficacious in augmenting muscle carnosine (+54% from mean baseline value) without side effects in patients with COPD in comparison with PL. However, accompanied beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress were not observed. BackgroundBeta‐alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes exercise capacity in healthy older adults. As patients with chronic obstructive pulmonary disease (COPD) suffer from elevated exercise‐induced muscle oxidative/carbonyl stress and acidosis, and from reduced muscle carnosine stores, it was investigated whether BA supplementation augments muscle carnosine and induces beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress in patients with COPD.MethodsIn this double‐blind, randomized, placebo (PL)‐controlled trial (clinicaltrials.gov identifier: NCT02770417), 40 patients (75% male) with COPD (mean ± standard deviation: age 65 ± 6 years; FEV1% predicted 55 ± 14%) were assigned to 12 weeks oral BA or PL supplementation (3.2 g/day). The primary outcome, i.e. muscle carnosine, was quantified from m. vastus lateralis biopsies obtained before and after intervention. Co‐primary outcomes, i.e. incremental and constant work rate cycle capacity, were also assessed. Linear mixed model analyses were performed. Compliance with and side effects of supplement intake and secondary outcomes (quadriceps strength and endurance, and muscle oxidative/carbonyl stress) were also assessed.ResultsBeta‐alanine supplementation increased muscle carnosine in comparison with PL in patients with COPD (mean difference [95% confidence interval]; +2.82 [1.49–4.14] mmol/kg wet weight; P < 0.001). Maximal incremental cycling capacity (VO2peak: +0.5 [−0.7 to 1.7] mL/kg/min; P = 0.384, Wpeak: +5 [−1 to 11] W; P = 0.103) and time to exhaustion on the constant work rate cycle test (+28 [−179 to 236] s; P = 0.782) did not change significantly. Compliance with supplement intake was similar in BA (median (quartile 1–quartile 3); 100 (98–100)%) and PL (98 (96–100)%) (P = 0.294) groups, and patients did not report side effects possibly related to supplement intake. No change was observed in secondary outcomes.ConclusionsBeta‐alanine supplementation is efficacious in augmenting muscle carnosine (+54% from mean baseline value) without side effects in patients with COPD in comparison with PL. However, accompanied beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress were not observed. Background Beta‐alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes exercise capacity in healthy older adults. As patients with chronic obstructive pulmonary disease (COPD) suffer from elevated exercise‐induced muscle oxidative/carbonyl stress and acidosis, and from reduced muscle carnosine stores, it was investigated whether BA supplementation augments muscle carnosine and induces beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress in patients with COPD. Methods In this double‐blind, randomized, placebo (PL)‐controlled trial (clinicaltrials.gov identifier: NCT02770417), 40 patients (75% male) with COPD (mean ± standard deviation: age 65 ± 6 years; FEV1% predicted 55 ± 14%) were assigned to 12 weeks oral BA or PL supplementation (3.2 g/day). The primary outcome, i.e. muscle carnosine, was quantified from m. vastus lateralis biopsies obtained before and after intervention. Co‐primary outcomes, i.e. incremental and constant work rate cycle capacity, were also assessed. Linear mixed model analyses were performed. Compliance with and side effects of supplement intake and secondary outcomes (quadriceps strength and endurance, and muscle oxidative/carbonyl stress) were also assessed. Results Beta‐alanine supplementation increased muscle carnosine in comparison with PL in patients with COPD (mean difference [95% confidence interval]; +2.82 [1.49–4.14] mmol/kg wet weight; P < 0.001). Maximal incremental cycling capacity (VO2peak: +0.5 [−0.7 to 1.7] mL/kg/min; P = 0.384, Wpeak: +5 [−1 to 11] W; P = 0.103) and time to exhaustion on the constant work rate cycle test (+28 [−179 to 236] s; P = 0.782) did not change significantly. Compliance with supplement intake was similar in BA (median (quartile 1–quartile 3); 100 (98–100)%) and PL (98 (96–100)%) (P = 0.294) groups, and patients did not report side effects possibly related to supplement intake. No change was observed in secondary outcomes. Conclusions Beta‐alanine supplementation is efficacious in augmenting muscle carnosine (+54% from mean baseline value) without side effects in patients with COPD in comparison with PL. However, accompanied beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress were not observed. Background: Beta-alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes exercise capacity in healthy older adults. As patients with chronic obstructive pulmonary disease (COPD) suffer from elevated exercise-induced muscle oxidative/carbonyl stress and acidosis, and from reduced muscle carnosine stores, it was investigated whether BA supplementation augments muscle carnosine and induces beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress in patients with COPD.Methods: In this double-blind, randomized, placebo (PL)-controlled trial (clinicaltrials.gov identifier: NCT02770417), 40 patients (75% male) with COPD (mean ± standard deviation: age 65 ± 6 years; FEV1 % predicted 55 ± 14%) were assigned to 12 weeks oral BA or PL supplementation (3.2 g/day). The primary outcome, i.e. muscle carnosine, was quantified from m. vastus lateralis biopsies obtained before and after intervention. Co-primary outcomes, i.e. incremental and constant work rate cycle capacity, were also assessed. Linear mixed model analyses were performed. Compliance with and side effects of supplement intake and secondary outcomes (quadriceps strength and endurance, and muscle oxidative/carbonyl stress) were also assessed.Results: Beta-alanine supplementation increased muscle carnosine in comparison with PL in patients with COPD (mean difference [95% confidence interval]; +2.82 [1.49-4.14] mmol/kg wet weight; P < 0.001). Maximal incremental cycling capacity (VO2 peak: +0.5 [-0.7 to 1.7] mL/kg/min; P = 0.384, Wpeak: +5 [-1 to 11] W; P = 0.103) and time to exhaustion on the constant work rate cycle test (+28 [-179 to 236] s; P = 0.782) did not change significantly. Compliance with supplement intake was similar in BA (median (quartile 1-quartile 3); 100 (98-100)%) and PL (98 (96-100)%) (P = 0.294) groups, and patients did not report side effects possibly related to supplement intake. No change was observed in secondary outcomes.Conclusions: Beta-alanine supplementation is efficacious in augmenting muscle carnosine (+54% from mean baseline value) without side effects in patients with COPD in comparison with PL. However, accompanied beneficial changes in exercise capacity, quadriceps function, and muscle oxidative/carbonyl stress were not observed. |
| Author | Derave, Wim Pomiès, Pascal Burtin, Chris Keytsman, Charly Hayot, Maurice Lima, Fabiano F. De Brandt, Jana Barusso‐Grüninger, Marina S. Spruit, Martijn A. Vandenabeele, Frank Blancquaert, Laura |
| AuthorAffiliation | 2 BIOMED ‐ Biomedical Research Institute Hasselt University Diepenbeek Belgium 6 Faculty of Science and Technology, Department of Physical Therapy, Postgraduate Program in Physical Therapy São Paulo State University (UNESP) Presidente Prudente São Paulo Brazil 1 Faculty of Rehabilitation Sciences, REVAL ‐ Rehabilitation Research Center Hasselt University Diepenbeek Belgium 5 LEFiR ‐ Spirometry and Respiratory Laboratory São Carlos Federal University ‐ UFSCar São Carlos São Paulo Brazil 3 Department of Movement and Sports Sciences Ghent University Ghent Belgium 4 PhyMedExp University of Montpellier – INSERM – CNRS – CHRU Montpellier Montpellier France 7 Department of Research and Education CIRO+ Horn The Netherlands 8 Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism Maastricht University Medical Centre Maastricht The Netherlands |
| AuthorAffiliation_xml | – name: 5 LEFiR ‐ Spirometry and Respiratory Laboratory São Carlos Federal University ‐ UFSCar São Carlos São Paulo Brazil – name: 8 Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism Maastricht University Medical Centre Maastricht The Netherlands – name: 2 BIOMED ‐ Biomedical Research Institute Hasselt University Diepenbeek Belgium – name: 6 Faculty of Science and Technology, Department of Physical Therapy, Postgraduate Program in Physical Therapy São Paulo State University (UNESP) Presidente Prudente São Paulo Brazil – name: 4 PhyMedExp University of Montpellier – INSERM – CNRS – CHRU Montpellier Montpellier France – name: 7 Department of Research and Education CIRO+ Horn The Netherlands – name: 3 Department of Movement and Sports Sciences Ghent University Ghent Belgium – name: 1 Faculty of Rehabilitation Sciences, REVAL ‐ Rehabilitation Research Center Hasselt University Diepenbeek Belgium |
| Author_xml | – sequence: 1 givenname: Jana orcidid: 0000-0003-3463-1911 surname: De Brandt fullname: De Brandt, Jana organization: Hasselt University – sequence: 2 givenname: Wim surname: Derave fullname: Derave, Wim organization: Ghent University – sequence: 3 givenname: Frank surname: Vandenabeele fullname: Vandenabeele, Frank organization: Hasselt University – sequence: 4 givenname: Pascal surname: Pomiès fullname: Pomiès, Pascal organization: University of Montpellier – INSERM – CNRS – CHRU Montpellier – sequence: 5 givenname: Laura surname: Blancquaert fullname: Blancquaert, Laura organization: Ghent University – sequence: 6 givenname: Charly surname: Keytsman fullname: Keytsman, Charly organization: Hasselt University – sequence: 7 givenname: Marina S. surname: Barusso‐Grüninger fullname: Barusso‐Grüninger, Marina S. organization: São Carlos Federal University ‐ UFSCar – sequence: 8 givenname: Fabiano F. surname: Lima fullname: Lima, Fabiano F. organization: São Paulo State University (UNESP) – sequence: 9 givenname: Maurice surname: Hayot fullname: Hayot, Maurice organization: University of Montpellier – INSERM – CNRS – CHRU Montpellier – sequence: 10 givenname: Martijn A. surname: Spruit fullname: Spruit, Martijn A. organization: Maastricht University Medical Centre – sequence: 11 givenname: Chris surname: Burtin fullname: Burtin, Chris email: chris.burtin@uhasselt.be organization: Hasselt University |
| BackLink | https://hal.science/hal-03753681$$DView record in HAL |
| BookMark | eNp9kk9u1DAUxiNUREvphhNYYsO_KXYcOw4LpGpUaFERC2BtOc5Lx4Njp3Yyo2HFETgCa47BUTgJnmaE1ArVGz_bv_c9P39-mO057yDLHhN8TDDOXy117I4JxYW4lx3kpMIzjnG1t4tZVZH97CjGJU6j4IQz_CDbp6wqy4qQg-zXadsarfQG-RaR_PfPNcDXiHxQFtUwqD_ffyirnHGA4tj3FjpwgxqMd8g41KcorSNam2GB9CJ4ZzTydRzCqAezAtSPtvNOhQ1qTAQV4TVSqPFjbSFJ19a45iUKyjW-M98gxb1VGmqfDrV3Q_DWQoOGYJR9lN1vlY1wtJsPsy9vTz_Pz2YXH9-dz08uZprlTMxY0UKLm5rWBddQYIGFEjnVDeYCWtXWFU0crzHhLTCoaooZIXkJtYa8wJoeZueTbuPVUvbBdOn60isjrzd8uJQqDEZbkIQT0ohUkbZNIYQWghGeY0KKVnAqyqT1YtIaXa82a2XtP0GC5dZAuTVQXhuY6DcT3Y91B41OT5t8uHGFmyfOLOSlX8mKpSY4SwLPJoHFrbSzkwu53cO0ZJQLsiKJfborFvzVCHGQnYkabHIb_BhlXmJaCc7yLfrkFrr0Y3DJhETluCxwKWiink-UDj7GAO3dreJbsDbTv0qNGfv_FDKlrI2FzR3i8v3804cp5y-h5wGe |
| CitedBy_id | crossref_primary_10_3389_fcimb_2023_1225991 crossref_primary_10_3390_antiox12071355 crossref_primary_10_3389_fendo_2024_1429159 crossref_primary_10_3390_nu15183902 crossref_primary_10_3390_nu15245136 crossref_primary_10_1183_20734735_0347_2023 crossref_primary_10_3390_nu15122741 crossref_primary_10_1007_s10989_023_10553_y crossref_primary_10_1016_j_pccm_2023_10_001 crossref_primary_10_1111_apha_14020 |
| Cites_doi | 10.1002/biof.5520240109 10.1016/j.jamda.2011.06.009 10.1007/s00726-018-2592-9 10.1080/026404198366443 10.1038/s41430-020-0596-5 10.3389/fnut.2019.00135 10.1007/s00726-011-1200-z 10.1164/ajrccm.153.1.8542131 10.1186/s12970-018-0238-7 10.1136/bjsports-2016-096396 10.1007/BF00376439 10.1007/s00421-009-1225-0 10.1007/s00726-011-1054-4 10.1016/j.ccm.2013.09.008 10.1249/MSS.0000000000001213 10.1152/ajpregu.00360.2020 10.1113/JP272050 10.1093/advances/nmy115 10.2147/JIR.S320659 10.1007/s00726-006-0299-9 10.1164/rccm.201710-2140CI 10.1136/bmjopen-2020-038836 10.1164/rccm.201402-0373ST 10.1007/s00726-011-1169-7 10.3389/fnut.2015.00013 10.1183/09031936.06.00110605 10.1017/S000711451800017X 10.1007/s00726-011-1190-x 10.1186/1550-2783-5-21 10.1016/j.exger.2013.06.003 10.1023/A:1012256521840 10.1186/s12970-015-0090-y 10.2147/COPD.S59164 10.1002/jcsm.12899 10.1152/physrev.00039.2012 10.1016/j.redox.2018.07.009 10.1183/09031936.00104909 10.3389/fphys.2020.00913 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution |
| Copyright_xml | – notice: 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. – notice: 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution |
| DBID | 24P AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM ADTOC UNPAY DOA |
| DOI | 10.1002/jcsm.13048 |
| DatabaseName | Wiley Online Library Open Access CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Beta‐alanine supplementation in COPD |
| EISSN | 2190-6009 |
| EndPage | 2372 |
| ExternalDocumentID | oai_doaj_org_article_1611d854f3fd488c8851620114f86387 10.1002/jcsm.13048 PMC9530565 oai:HAL:hal-03753681v1 10_1002_jcsm_13048 JCSM13048 |
| Genre | article |
| GeographicLocations | Belgium United States--US |
| GeographicLocations_xml | – name: United States--US – name: Belgium |
| GrantInformation_xml | – fundername: FWO funderid: 11B4718N – fundername: São Paulo Research Foundation (FAPESP) funderid: 2019/10744‐3 – fundername: Limburgs Kankerfonds – fundername: ; grantid: 11B4718N – fundername: ; grantid: 2019/10744‐3 |
| GroupedDBID | --- 0R~ 1OC 24P 2VQ 4.4 40G 53G 5VS 7X7 8FI 8FJ AAHHS AAKDD AAZKR ABUWG ACCFJ ACCMX ACXQS ADBBV ADINQ ADKYN ADPDF ADRAZ ADZMN ADZOD AEEZP AENEX AEQDE AFKRA AHBYD AHSBF AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AOIJS AVUZU AZFZN BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK EBS EJD EMOBN FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH ITC KQ8 M48 M~E O9- OK1 OVD OVEED PIMPY PQQKQ PROAC RPM RSV SMD SOJ U2A UKHRP WIN ZOVNA AAFWJ AAMMB AAYXX AEFGJ AFPKN AGXDD AIDQK AIDYY CITATION PHGZM PHGZT PUEGO 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 1XC VOOES 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c5258-54fef0db3b46ce40808a823cd068efafb935256b016fe5e9b3051127ebce240c3 |
| IEDL.DBID | DOA |
| ISSN | 2190-5991 2190-6009 |
| IngestDate | Fri Oct 03 12:42:41 EDT 2025 Sun Oct 26 03:29:35 EDT 2025 Tue Sep 30 17:19:35 EDT 2025 Tue Oct 14 20:44:05 EDT 2025 Fri Sep 05 11:30:40 EDT 2025 Tue Oct 07 06:56:06 EDT 2025 Wed Oct 01 03:24:47 EDT 2025 Thu Apr 24 23:06:46 EDT 2025 Wed Jan 22 16:24:07 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Carnosine Chronic obstructive pulmonary disease Physical capacity Oxidative/carbonyl stress |
| Language | English |
| License | Attribution Attribution: http://creativecommons.org/licenses/by This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5258-54fef0db3b46ce40808a823cd068efafb935256b016fe5e9b3051127ebce240c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Clinical Trial Registration: clinicaltrials.gov identifier: NCT02770417 (https://www.clinicaltrials.gov/ct2/show/NCT02770417?term=NCT02770417&draw=2&rank=1). |
| ORCID | 0000-0003-3463-1911 0000-0002-5301-6087 0000-0001-6388-1114 |
| OpenAccessLink | https://doaj.org/article/1611d854f3fd488c8851620114f86387 |
| PMID | 35977911 |
| PQID | 2720740783 |
| PQPubID | 4370305 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1611d854f3fd488c8851620114f86387 unpaywall_primary_10_1002_jcsm_13048 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9530565 hal_primary_oai_HAL_hal_03753681v1 proquest_miscellaneous_2703986521 proquest_journals_2720740783 crossref_primary_10_1002_jcsm_13048 crossref_citationtrail_10_1002_jcsm_13048 wiley_primary_10_1002_jcsm_13048_JCSM13048 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2022 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: October 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | Heidelberg |
| PublicationPlace_xml | – name: Heidelberg – name: Hoboken |
| PublicationTitle | Journal of cachexia, sarcopenia and muscle |
| PublicationYear | 2022 |
| Publisher | John Wiley & Sons, Inc Wiley Open Access/Springer Verlag John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Open Access/Springer Verlag – name: John Wiley and Sons Inc – name: Wiley |
| References | 2015; 2 2015; 12 2013; 48 2006; 30 2010; 36 2019; 6 2010; 108 2019; 10 2017; 49 2013; 93 2008; 5 2020; 11 2020; 10 1985; 2021 2012; 13 2001; 225 2005; 24 1998; 16 2017; 51 2021; 14 2018; 18 2018; 198 2021; 12 2022 2018; 119 2021 2020 2006; 27 1985; 2018 2016; 594 2017 2014; 35 1985; 2014 1985; 2013 1996; 153 2018; 50 1992; 64 2014; 9 2012; 43 2018; 15 2012; 42 2014; 189 e_1_2_9_30_1 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 Blancquaert L (e_1_2_9_31_1) 2017 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_18_1 GOLD (e_1_2_9_20_1) 2022 Hoetker D (e_1_2_9_34_1) 1985; 2018 e_1_2_9_41_1 e_1_2_9_40_1 De Brandt J (e_1_2_9_6_1) 1985; 2021 e_1_2_9_45_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_5_1 Borst B (e_1_2_9_22_1) 1985; 2013 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 Bex T (e_1_2_9_42_1) 1985; 2014 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 |
| References_xml | – volume: 225 start-page: 29 year: 2001 end-page: 34 article-title: In vitro and in vivo inhibition of muscle lipid and protein oxidation by carnosine publication-title: Mol Cell Biochem – volume: 24 start-page: 77 year: 2005 end-page: 87 article-title: Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives publication-title: Biofactors – volume: 18 start-page: 222 year: 2018 end-page: 228 article-title: Exercise and β‐alanine supplementation on carnosine‐acrolein adduct in skeletal muscle publication-title: Redox Biol – volume: 5 start-page: 21 year: 2008 article-title: The effect of beta‐alanine supplementation on neuromuscular fatigue in elderly (55–92 years): a double‐blind randomized study publication-title: J Int Soc Sports Nutr – volume: 35 start-page: 51 year: 2014 end-page: 69 article-title: Chronic obstructive pulmonary disease: clinical integrative physiology publication-title: Clin Chest Med – volume: 42 start-page: 2461 year: 2012 end-page: 2472 article-title: Effect of two β‐alanine dosing protocols on muscle carnosine synthesis and washout publication-title: Amino Acids – volume: 50 start-page: 1177 year: 2018 end-page: 1186 article-title: Carnosine and advanced glycation end products: a systematic review publication-title: Amino Acids – start-page: 201 year: 2017 – volume: 16 start-page: 639 year: 1998 end-page: 643 article-title: Carnosine and taurine contents in individual fibres of human vastus lateralis muscle publication-title: J Sports Sci – volume: 43 start-page: 67 year: 2012 end-page: 76 article-title: Effect of slow‐release β‐alanine tablets on absorption kinetics and paresthesia publication-title: Amino Acids – volume: 14 start-page: 4503 year: 2021 end-page: 4507 article-title: Monomeric CRP is elevated in patients with COPD compared to non‐COPD control persons publication-title: J Inflamm Res – volume: 10 year: 2020 article-title: Beta‐alanine supplementation in patients with COPD receiving non‐linear periodised exercise training or neuromuscular electrical stimulation: protocol of two randomised, double‐blind, placebo‐controlled trials publication-title: BMJ Open – volume: 594 start-page: 4849 year: 2016 end-page: 4863 article-title: Carnosine and anserine homeostasis in skeletal muscle and heart is controlled by β‐alanine transamination publication-title: J Physiol – volume: 6 start-page: 135 year: 2019 article-title: Can the skeletal muscle carnosine response to beta‐alanine supplementation be optimized? publication-title: Front Nutr – volume: 64 start-page: 47 year: 1992 end-page: 50 article-title: Carnosine and anserine concentrations in the quadriceps femoris muscle of healthy humans publication-title: Eur J Appl Physiol Occup Physiol – volume: 108 start-page: 495 year: 2010 end-page: 503 article-title: β‐Alanine supplementation reduces acidosis but not oxygen uptake response during high‐intensity cycling exercise publication-title: Eur J Appl Physiol – volume: 36 start-page: 81 year: 2010 end-page: 88 article-title: The prevalence of quadriceps weakness in COPD and the relationship with disease severity publication-title: Eur Respir J – volume: 51 start-page: 658 year: 2017 end-page: 669 article-title: β‐alanine supplementation to improve exercise capacity and performance: a systematic review and meta‐analysis publication-title: Br J Sports Med – volume: 30 start-page: 279 year: 2006 end-page: 289 article-title: The absorption of orally supplied β‐alanine and its effect on muscle carnosine synthesis in human vastus lateralis publication-title: Amino Acids – volume: 13 start-page: 291 year: 2012 end-page: 297 article-title: Predicting outcomes from 6‐minute walk distance in chronic obstructive pulmonary disease publication-title: J Am Med Dir Assoc – volume: 2 start-page: 13 year: 2015 article-title: Exercise training and beta‐alanine‐induced muscle carnosine loading publication-title: Front Nutr – year: 2020 article-title: Reference values of body composition parameters and visceral adipose tissue (VAT) by DXA in adults aged 18–81 years—results from the LEAD cohort publication-title: Eur J Clin Nutr – volume: 2014 start-page: 204 year: 1985 end-page: 209 article-title: Muscle carnosine loading by beta‐alanine supplementation is more pronounced in trained vs. untrained muscles publication-title: J Appl Physiol – volume: 93 start-page: 1803 year: 2013 end-page: 1845 article-title: Physiology and pathophysiology of carnosine publication-title: Physiol Rev – volume: 2013 start-page: 1319 year: 1985 end-page: 1328 article-title: Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild‐to‐moderate COPD publication-title: J Appl Physiol – volume: 43 start-page: 25 year: 2012 end-page: 37 article-title: Effects of β‐alanine supplementation on exercise performance: a meta‐analysis publication-title: Amino Acids – volume: 27 start-page: 1110 year: 2006 end-page: 1118 article-title: Cardiopulmonary stress during exercise training in patients with COPD publication-title: Eur Respir J – volume: 49 start-page: 602 year: 2017 end-page: 609 article-title: Effects of histidine and β‐alanine supplementation on human muscle carnosine storage publication-title: Med Sci Sports Exerc – volume: 9 start-page: 589 year: 2014 end-page: 595 article-title: Ventilatory requirements of quadriceps resistance training in people with COPD and healthy controls publication-title: Int J Chron Obstruct Pulmon Dis – volume: 2018 year: 1985 article-title: Exercise alters and β‐alanine combined with exercise augments histidyl dipeptide levels and scavenges lipid peroxidation products in human skeletal muscle publication-title: J Appl Physiol – volume: 198 start-page: 175 year: 2018 end-page: 186 article-title: Skeletal muscle dysfunction in chronic obstructive pulmonary disease. What we know and can do for our patients publication-title: Am J Respir Crit Care Med – volume: 10 start-page: 452 year: 2019 end-page: 463 article-title: A systematic risk assessment and meta‐analysis on the use of oral β‐alanine supplementation publication-title: Adv Nutr – volume: 189 start-page: e15 year: 2014 end-page: e62 article-title: An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease publication-title: Am J Respir Crit Care Med – year: 2022 – volume: 12 start-page: 30 year: 2015 article-title: International society of sports nutrition position stand: beta‐alanine publication-title: J Int Soc Sports Nutr – volume: 11 start-page: 913 year: 2020 article-title: The muscle carnosine response to beta‐alanine supplementation: a systematic review with Bayesian individual and aggregate data E‐max model and meta‐analysis publication-title: Front Physiol – year: 2021 article-title: The role of chronic muscle (in)activity on carnosine homeostasis: a study with spinal‐cord injured athletes publication-title: Am J Physiol Regul Integr Comp Physiol – volume: 48 start-page: 933 year: 2013 end-page: 939 article-title: Oral nutritional supplement fortified with beta‐alanine improves physical working capacity in older adults: a randomized, placebo‐controlled study publication-title: Exp Gerontol – volume: 2021 year: 1985 article-title: Carnosine, oxidative and carbonyl stress, antioxidants and muscle fiber characteristics of quadriceps muscle of patients with COPD publication-title: J Appl Physiol – volume: 12 start-page: 2259 year: 2021 end-page: 2261 article-title: Ethical guidelines for publishing in the : update 2021 publication-title: J Cachexia Sarcopenia Muscle – volume: 15 start-page: 32 year: 2018 article-title: β‐Alanine supplementation increased physical performance and improved executive function following endurance exercise in middle aged individuals publication-title: J Int Soc Sports Nutr – volume: 119 start-page: 759 year: 2018 end-page: 770 article-title: Changing to a vegetarian diet reduces the body creatine pool in omnivorous women, but appears not to affect carnitine and carnosine homeostasis: a randomised trial publication-title: Br J Nutr – volume: 153 start-page: 288 year: 1996 end-page: 293 article-title: Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD publication-title: Am J Respir Crit Care Med – volume: 43 start-page: 49 year: 2012 end-page: 56 article-title: Beta‐alanine (Carnosyn) supplementation in elderly subjects (60–80 years): effects on muscle carnosine content and physical capacity publication-title: Amino Acids – ident: e_1_2_9_8_1 doi: 10.1002/biof.5520240109 – start-page: 201 volume-title: Muscle Carnosine Homeostasis: A Unique Set of Regulatory Mechanisms year: 2017 ident: e_1_2_9_31_1 – ident: e_1_2_9_39_1 doi: 10.1016/j.jamda.2011.06.009 – ident: e_1_2_9_9_1 doi: 10.1007/s00726-018-2592-9 – ident: e_1_2_9_5_1 doi: 10.1080/026404198366443 – ident: e_1_2_9_40_1 doi: 10.1038/s41430-020-0596-5 – ident: e_1_2_9_24_1 doi: 10.3389/fnut.2019.00135 – ident: e_1_2_9_38_1 doi: 10.1007/s00726-011-1200-z – ident: e_1_2_9_3_1 doi: 10.1164/ajrccm.153.1.8542131 – volume: 2018 year: 1985 ident: e_1_2_9_34_1 article-title: Exercise alters and β‐alanine combined with exercise augments histidyl dipeptide levels and scavenges lipid peroxidation products in human skeletal muscle publication-title: J Appl Physiol – ident: e_1_2_9_18_1 doi: 10.1186/s12970-018-0238-7 – ident: e_1_2_9_17_1 doi: 10.1136/bjsports-2016-096396 – ident: e_1_2_9_10_1 doi: 10.1007/BF00376439 – ident: e_1_2_9_11_1 doi: 10.1007/s00421-009-1225-0 – ident: e_1_2_9_26_1 doi: 10.1007/s00726-011-1054-4 – ident: e_1_2_9_33_1 doi: 10.1016/j.ccm.2013.09.008 – ident: e_1_2_9_29_1 doi: 10.1249/MSS.0000000000001213 – ident: e_1_2_9_43_1 doi: 10.1152/ajpregu.00360.2020 – ident: e_1_2_9_27_1 doi: 10.1113/JP272050 – ident: e_1_2_9_13_1 doi: 10.1093/advances/nmy115 – ident: e_1_2_9_19_1 doi: 10.2147/JIR.S320659 – volume-title: The Global Strategy for Diagnosis, Management and Prevention of COPD year: 2022 ident: e_1_2_9_20_1 – ident: e_1_2_9_23_1 doi: 10.1007/s00726-006-0299-9 – ident: e_1_2_9_32_1 doi: 10.1164/rccm.201710-2140CI – ident: e_1_2_9_44_1 doi: 10.1136/bmjopen-2020-038836 – volume: 2013 start-page: 1319 year: 1985 ident: e_1_2_9_22_1 article-title: Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild‐to‐moderate COPD publication-title: J Appl Physiol – volume: 2014 start-page: 204 year: 1985 ident: e_1_2_9_42_1 article-title: Muscle carnosine loading by beta‐alanine supplementation is more pronounced in trained vs. untrained muscles publication-title: J Appl Physiol – ident: e_1_2_9_2_1 doi: 10.1164/rccm.201402-0373ST – ident: e_1_2_9_28_1 doi: 10.1007/s00726-011-1169-7 – ident: e_1_2_9_41_1 doi: 10.3389/fnut.2015.00013 – ident: e_1_2_9_36_1 doi: 10.1183/09031936.06.00110605 – volume: 2021 year: 1985 ident: e_1_2_9_6_1 article-title: Carnosine, oxidative and carbonyl stress, antioxidants and muscle fiber characteristics of quadriceps muscle of patients with COPD publication-title: J Appl Physiol – ident: e_1_2_9_30_1 doi: 10.1017/S000711451800017X – ident: e_1_2_9_12_1 doi: 10.1007/s00726-011-1190-x – ident: e_1_2_9_15_1 doi: 10.1186/1550-2783-5-21 – ident: e_1_2_9_14_1 doi: 10.1016/j.exger.2013.06.003 – ident: e_1_2_9_7_1 doi: 10.1023/A:1012256521840 – ident: e_1_2_9_16_1 doi: 10.1186/s12970-015-0090-y – ident: e_1_2_9_37_1 doi: 10.2147/COPD.S59164 – ident: e_1_2_9_45_1 doi: 10.1002/jcsm.12899 – ident: e_1_2_9_4_1 doi: 10.1152/physrev.00039.2012 – ident: e_1_2_9_35_1 doi: 10.1016/j.redox.2018.07.009 – ident: e_1_2_9_21_1 doi: 10.1183/09031936.00104909 – ident: e_1_2_9_25_1 doi: 10.3389/fphys.2020.00913 |
| SSID | ssj0000461650 |
| Score | 2.3680165 |
| Snippet | Background
Beta‐alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading... BackgroundBeta‐alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading... Beta-alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine loading promotes... Background: Beta-alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle. Carnosine... Abstract Background Beta‐alanine (BA) supplementation increases muscle carnosine, an abundant endogenous antioxidant and pH buffer in skeletal muscle.... |
| SourceID | doaj unpaywall pubmedcentral hal proquest crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 2361 |
| SubjectTerms | Acidosis Airway management Biopsy Body mass index Carnosine Chronic obstructive pulmonary disease Comorbidity Double-blind studies Dyspnea Exercise Life Sciences Lung diseases Medical research Metabolites Older people Original Oxidative/carbonyl stress Physical capacity Physical fitness Steroids Stress analysis |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dbtMwFLZGJwE3iF8tYyADuwERrUlsJ0FCaJs6VROtEDBpd5H_wgpZ0q3rpnLFI_AavBZPwjmuG1aEehfFR4liHx9_8Tn-PkK2hcmFNrIbSsU4_KBIESolTaiNTsuEWask7ncMhqJ_xA6P-fEaGS7OwmBZ5SImukBtGo175DuYL0xd0und-CxE1SjMri4kNKSXVjBvHcXYDbIeIzNWh6zv9YYfPra7LkgvLpxsa4xnqDmgo5azNN75qienKI-MYkDXVilH5g9rzwmWSl7Dof9WUd6a1mM5u5JVtYx03VJ1cJfc8RiT7s6d4h5Zs_V9cnPgs-gPyK8e8kZIPaNNSaOYXln7bULxqD5V9kL-_vET6x3BlE5Q83NeX44DSEc19USsE4o7uFTPuXVpozwR7aWl42kFnSXPZ9Rnf95QSU0zVZWFRyvAteY1hSXSNKej7xauXV2YaqDRF85X1lAnJ_KQHB30Pu_3Qy_ZEGoe8yzkrLRl16hEMaEtAziaySxOtOmKzJayVDnSrwoFQLO03OYKwg0gvtQqbQFb6OQR6dRNbTcITUppEssTFTHNeM6kMlIj4WAeGW0YD8jLxRAV2vOZo6xGVcyZmOMCh7NwwxmQF63teM7i8V-rPRzp1gKZt92N5vxL4SdyAQg5Mhl8Z1IaCH46A8gqEEWxMoNYlgbkOfjJ0jP6u-8LvIdyw4nIossoIFsLNyp8zJgUfz08IM_aZpjtmMKRtW2maNNN8kwA5gpIuuR-S29cbqlHJ443POf4vwgdt9066sreeOV8eIVJcbj_aeCuNld_0GNyO8ZjI64Icot0wCPtEwBzF-qpn6F_AACeT2E priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZKkYAL4lcECjLQC4jAJrGdBAmhUrVaVSwXWKm3yH-hC2mybLoty4lH4BE48xg8Ck_CjNcbNajqiVsUz2YVz9j-nBl_HyGbwuRCGzkIpWIcNihShEpJE2qj0zJh1iqJ3ztG78RwzPb2-f4aWel3-g5sz9zaoZ7UeFY9__pl8RoG_CtPIPrik24PUdWYZRfIRVihcpRwGHmY72ZkJiLhxFpjPDnNARN1TKWnf95bmxyFP6w4B1ggeQp9_ls7eXleT-XiRFZVH9-6BWr3GrnqkSXdWobCdbJm6xvk0sjnzm-SXzvIFiH1gjYljeLfP0-s_dxSPKFPlT2Sf77_wDJHsKUtSn0uy8rRb3RSU8-_2lL8cEv1klKXNsrzzx5bOp1XENJytqA-6fOSSmqauaosPFoBnDXPKKyMpjmcfLNw7crBVAONvl6-soY6FZFbZLy782F7GHqlhlDzmGchZ6UtB0YligltGaDQTGZxos1AZLaUpcqRdVUowJel5TZXMMsA0Eut0hYcppPbZL1uanuH0KSUJrE8URHTjOdMKiM18gzmkdGG8YA8Wfmo0J7GHNU0qmJJwBwX6M_C-TMgjzvb6ZK840yrN-jqzgIJt92NZvax8OO3AGAcmQzeMykNzHk6A6QqEDyxMoMpLA3IIwiU3jOGW28LvIcqw4nIouMoIBurOCpWkV5gIjx12dSAPOyaYZBj5kbWtpmjzSDJMwFQKyBpL_56_9hvqScHji4857hNhI7b7CL13N546oL4HJNib_v9yF3d_R9dd49cifFMiauQ3CDrELf2PiC9I_XADeO_wTZYRw priority: 102 providerName: Scholars Portal – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELZgKwEX_isCBRnoBUTKJrGzCbelarWq2AoJViqnyH-hS9NkRXZbtScegUfgzGPwKDwJM4432lSoQuJmxbPe2BrPfPGMvyFkM9ZprLTo-0IyDh8oIvalFNpXWg3yiBkjBZ53jPfj0YTtHfCDlVv8DT9Ee-CGO8Paa9zgM503dt5F98PXX1R9jPWMWXKVrMUc0HiPrE323w8_YU05vCXNU1s0z7bBt6ctQ-nqjzs-yVL3g6c5xMTIFdR5MWfy-qKcibNTURRdXGsd0-4tIpZTavJRjrYWc7mlzi-wPf7PnG-Tmw610mGjZnfIFVPeJdfGLi5_j_zcQSYKoc5oldMg_PXj1JijmuLtfyrNXPz-9h1TKEGW1lhGtElZR52g05I6btea4qEwVQ1dL62k47Y9MXS2KGC7wHtTF1B6QwXV1UIWBoaWMDH9ioLX1dXx9NxA26aayQo6XS5-YTS1FUruk8nuzsftke-qQPiKhzzxOctN3tcykixWhgHCTUQSRkr348TkIpcpMrrGErBrbrhJJVgwAJEDI5UBuKKiddIrq9I8IDTKhY4Mj2TAFOMpE1ILhRyGaaCVZtwjL5Z6kClHkY6VOoqsIXcOM1z8zC6-R563srOGGOSvUm9RnVoJJPO2D6qvnzNnGzIA3YFOYJ5RrsGeqgRQcIzAjOUJmMeBR56BMnbGGA3fZfgMKxhHcRKcBB7ZWOpq5sxQnWGQfWAjtR552naDAcGokChNtUCZfpQmMcA4jww6Ot75x25POT20VOQpx09QWLjNdjdcuhovrXZfIpLtbX8Y29bDfxvzEbkR4o0Um1-5QXqgmeYx4MS5fOJMwR_cJm9Y priority: 102 providerName: Unpaywall – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwELZKkYAL4lcECjLQC4iom8T2JohLqVqtKhYhQaXeIv9M2oU0WZFuq3LiEXgEzjwGj8KTMONkU4JQJW5RPJtVPD_-4hl_w9i6cpmyTo9CbYTEDxStQmO0C62z4yIRAEbTfsf0rZrsid19ub_CXi3PwrT8EP2GG3mGj9fk4No0G-ekoR9tc0S9jEV6iV2OEMiQfcfiXb_DQlTiyrdojem8tEQk1POTxhvnPx-sSJ64H9eZQyqL_ANz_l0xeXVRzfXZqS7LIar1y9LODXa9w5N8szWAm2wFqlvsyrTLmN9mP7aJI0LbM14XPIp_fj8F-NRwOpfPDRzrX1-_UXEjyvKGGny2xeSkLT6reMe62nDaruW2JdLltelYZ0-AzxclGjLOIu9SPS-55q5emBLw0Qan2b3guB66-mj2BfDaF4GZGge7KvkSHPe9Q-6wvZ3tD1uTsOvPEFoZyzSUooBi5ExihLIgEHumOo0T60YqhUIXJiOuVWUQVRYgITMYWxDejcFYQCBhk7tstaoruMd4UmiXgExMJKyQmdDGaUvsglnkrBMyYM-WOsptR15OPTTKvKVdjnPSZ-71GbCnvey8pez4p9RrUnUvQTTb_kb9-SDvvDZHOBy5FN8zKRxGOpsiPlUEmUSRYuAaB-wJGsrgGZPNNzndo97CiUqjkyhga0s7yrsA0eSU_h77HGrAHvfD6NqUr9EV1AuSGSVZqhBgBWw8sL_BPw5HqtmhJwnPJH0c4sSt95Z64Ww890Z8gUi-u_V-6q_u_4_wA3YtphMjvv5xja2ifcJDxHHH5pF319__wktV priority: 102 providerName: Wiley-Blackwell |
| Title | Efficacy of 12 weeks oral beta‐alanine supplementation in patients with chronic obstructive pulmonary disease: a double‐blind, randomized, placebo‐controlled trial |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcsm.13048 https://www.proquest.com/docview/2720740783 https://www.proquest.com/docview/2703986521 https://hal.science/hal-03753681 https://pubmed.ncbi.nlm.nih.gov/PMC9530565 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcsm.13048 https://doaj.org/article/1611d854f3fd488c8851620114f86387 |
| UnpaywallVersion | publishedVersion |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: KQ8 dateStart: 20100901 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: GX1 dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: 7X7 dateStart: 20100901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: BENPR dateStart: 20100901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2190-6009 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: M48 dateStart: 20100901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Open Access Hybrid - NESLI2 2011-2012 customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: 40G dateStart: 20100101 isFulltext: true titleUrlDefault: http://link.springer.com/ providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: U2A dateStart: 20100901 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature – providerCode: PRVWIB databaseName: KBPluse Wiley Online Library: Open Access customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: AVUZU dateStart: 20100901 isFulltext: true titleUrlDefault: https://www.kbplus.ac.uk/kbplus7/publicExport/pkg/559 providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: 24P dateStart: 20100101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtNAEF5BkYAL4lcYSrRALyCsxvbues0trVJFFYkiIFI5WftnNeDaEWlahROPwCNw5jF4FJ6EmbUbJQiVCxfL2h05ys7n3W89s98QsiNsJoxV3VBpxmGDokSotbKhsSYtEuacVvi9YzgSgwk7POJHa6W-MCeskQduBm4XGElkJWdFUlgAm5FAEQSuWqyQgB1_jrwrs7XNlJ-DmYiEL88a41lpDixopU0a73408xMsg4xFf9ZWIy_aD2vMMaZErvHNP7MlbyyqmVqeq7LcZLR-STq4TW61XJL2mv9wh1xx1V1yfdhGy--RH33Uh1BmSeuCRvHP7-fOfZpTPJNPtTtVv75-w8RGsKVzLO7ZJJKjp-i0oq3i6pzip1pqGhFdWutWcfbM0dmiBBCrz0vahnleU0VtvdClg0drILD2FYW10NYn0y8O7n0CmK6hs82QL52lvm7IfTI56L_fH4RtbYbQ8JjLEBziiq7ViWbCOAa8UyoZJ8Z2hXSFKnSGOqtCA6MsHHeZhnkFqF3qtHFAIkzygGxVdeUeEpoUyiaOJzpihvGMKW2VQWXBLLLGMh6QFxc-yk0rXI71M8q8kVyOc_Rn7v0ZkOcr21kj1_FXqz109coCJbZ9AwAvb4GX_wt4AXkGQNl4xqD3Jsc2rCucCBmdRQHZvsBR3k4O8xxD36mPnwbk6aobXmuM1ajK1Qu06SaZFECuApJu4G_jFzd7qumxFwjPOG4MYeB2Vki9dDReehBfYpIf7r8b-rtH_2PoHpObMZ4i8TmR22QLcOueALc71R1yNWZjuKZHaYdc2-uPxm87_tWG65BJaJuMxr0PvwGvQFaB |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VVqJcEL_CpcAC5QDCamyvHRupQm1JlbZJhKCVejP75zbg2qFuGoUTj8Br8BI8DE_CzGZjGoRy682yR2vZMzv77e7s9xGyFqkkkoo3XC5YCBMUHrlCcOVKJZtZwLQWHNc7ur2ofcj2jsKjBfJrehYGyyqnOdEkalVKXCNfx_3Cptl0ejv46qJqFO6uTiU0uJVWUBuGYswe7NjX4xFM4aqN3Xfg7xe-v9M62G67VmXAlaEfxm7IMp01lAgEi6RmgKBiHvuBVI0o1hnPRIKMoZEAbJTpUCcCegiAlKYWUsNwKANo9xpZYgFLYPK3tNXqvf9Qr_IgnXlkZGJ9PLMdAhqrOVL99c-yOkU5ZhQfujQqGvEAGOtOsDTzEu79t2pzeVgM-HjE83wWWZuhcecWuWkxLd2cBOFtsqCLO-R61-7a3yU_W8hTweWYlhn1fDrS-ktFkRqACn3Of3__gfWVYEor1Bid1LNjwNB-QS3xa0VxxZjKCZcvLYUlvr3QdDDMwTn8bEztbtMbyqkqhyLX0LQAHK1eUxiSVXna_6bh2tShiRIe2kL9XCtq5EvukcMrcd59sliUhX5AaJBxFegwEB6TLEwYF4pLJDhMPCUVCx3ycuqiVFr-dJTxyNMJ87OfojtT406HPK9tBxPWkP9abaGnawtk-jY3yrPj1CaOFBC5p2L4ziBTkGxlDBA5QtTGshhyZ9MhzyBOZtpob3ZSvIfyxkEUexeeQ1anYZTaHFWlf3uUQ57WjyG74JYRL3Q5RJtGkMQRYDyHNGfCb-aNs0-K_onhKU9CnJ_Cj1urA3Xu33hlYniOSbq3_bFrrlbmf9ATstw-6HbSzm5v_yG54eORFVOAuUoWITr1IwCS5-Kx7a2UfLrqBPEH6SeMRQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELVKkQoviKsIFDBQHkBEu4njXJAQKm1X28tWSFBp34JvoQtpsjTdrpYnPoHf4Bf4HL6EGScbugj1rW9RPHIUz3h87BmfIWQt1EmotOi6QgYcNigidKUU2lVaRRkLjJECzzsG-2H_INgZ8uES-TW_C4NplXOfaB21LhWekXcwXhjZoFMna9Ii3m323oy_ulhBCiOt83IatYnsmtkUtm_V6-1N0PUz3-9tfdjou02FAVdxn8cuDzKTdbVkMgiVCQA9xSL2mdLdMDaZyGSCbKGhBFyUGW4SCbMDAEpkpDKwFCoG_V4ilyPGEkwnjIZRe76DROahLRDr421tDjisZUf1O59VdYSFmLHs0Jn10JYNgFXuEJMyzyDef_M1r0yKsZhNRZ4vYmq7KPauk2sNmqXrtfndIEumuElWBk28_hb5uYUMFULNaJlRz6dTY75UFEkBqDQn4vf3H5hZCaK0wuqidSY7mgodFbShfK0onhVTVbP40lI2lLenho4nOahCHM9oE2d6RQXV5UTmBrqWgKD1SwqLsS6PRt8MPNsMNFlCY5OinxtNbeGS2-TgQlR3hywXZWHuEsoyoZnhTHqBCngSCKmFQmrDxNNKB9whz-cqSlXDnI4FPPK05nz2U1RnatXpkKet7LjmC_mv1FvUdCuBHN_2RXn8KW1cRgpY3NMx_CfLNLhZFQM4DhGvBVkMXjNyyBOwk4U--ut7Kb7DwsYsjL1TzyGrczNKG-9UpX_nkkMet83gVzBYJApTTlCmy5I4BHTnkGjB_Ba-uNhSjA4tQ3nCcWcKA7fWGuq5o_HC2vA5IunOxvuBfbp3_g89IivgFtK97f3d--Sqj3dVbOblKlkG4zQPAEGeyId2qlLy8aJ9wx8iJYnf |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELZgKwEX_isCBRnoBUTKJrGzCbelarWq2AoJViqnyH-hS9NkRXZbtScegUfgzGPwKDwJM4432lSoQuJmxbPe2BrPfPGMvyFkM9ZprLTo-0IyDh8oIvalFNpXWg3yiBkjBZ53jPfj0YTtHfCDlVv8DT9Ee-CGO8Paa9zgM503dt5F98PXX1R9jPWMWXKVrMUc0HiPrE323w8_YU05vCXNU1s0z7bBt6ctQ-nqjzs-yVL3g6c5xMTIFdR5MWfy-qKcibNTURRdXGsd0-4tIpZTavJRjrYWc7mlzi-wPf7PnG-Tmw610mGjZnfIFVPeJdfGLi5_j_zcQSYKoc5oldMg_PXj1JijmuLtfyrNXPz-9h1TKEGW1lhGtElZR52g05I6btea4qEwVQ1dL62k47Y9MXS2KGC7wHtTF1B6QwXV1UIWBoaWMDH9ioLX1dXx9NxA26aayQo6XS5-YTS1FUruk8nuzsftke-qQPiKhzzxOctN3tcykixWhgHCTUQSRkr348TkIpcpMrrGErBrbrhJJVgwAJEDI5UBuKKiddIrq9I8IDTKhY4Mj2TAFOMpE1ILhRyGaaCVZtwjL5Z6kClHkY6VOoqsIXcOM1z8zC6-R563srOGGOSvUm9RnVoJJPO2D6qvnzNnGzIA3YFOYJ5RrsGeqgRQcIzAjOUJmMeBR56BMnbGGA3fZfgMKxhHcRKcBB7ZWOpq5sxQnWGQfWAjtR552naDAcGokChNtUCZfpQmMcA4jww6Ot75x25POT20VOQpx09QWLjNdjdcuhovrXZfIpLtbX8Y29bDfxvzEbkR4o0Um1-5QXqgmeYx4MS5fOJMwR_cJm9Y |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+12%C2%A0weeks+oral+beta%E2%80%90alanine+supplementation+in+patients+with+chronic+obstructive+pulmonary+disease%3A+a+double%E2%80%90blind%2C+randomized%2C+placebo%E2%80%90controlled+trial&rft.jtitle=Journal+of+cachexia%2C+sarcopenia+and+muscle&rft.au=Jana+De+Brandt&rft.au=Wim+Derave&rft.au=Frank+Vandenabeele&rft.au=Pascal+Pomi%C3%A8s&rft.date=2022-10-01&rft.pub=Wiley&rft.issn=2190-5991&rft.eissn=2190-6009&rft.volume=13&rft.issue=5&rft.spage=2361&rft.epage=2372&rft_id=info:doi/10.1002%2Fjcsm.13048&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1611d854f3fd488c8851620114f86387 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-5991&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-5991&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-5991&client=summon |